Techs or pharmeceuticals — which is the better buy for investors? Uri Landesman, president of Platinum Partners, and Philip Tasho, chief executive and chief investment officer at Tamro Capital, shared their insights.
Techs Are Still the Way to Go:
Research In Motion—“We focus on undervalued companies that have a sustainable competitive advantage and that’s what we see with RIM,” Tasho told CNBC.
“They are the leader second only to Nokia globally in the smartphone market.”
“We don’t believe Apple’s going to put them out of business,” he added. “More than 50 percent of their revenues are from overseas and that’s the fastest growing component of the market.”
Google—“Search is really the heart of the web,” he said. “And when people go online, the first thing they do is search and [Google is] able to monetize that beautifully—they facilitate 20 percent of e-commerce, second only to Amazon.com .”
In addition, Tasho also likes Range Resources .
The Case For Pharmaceuticals:
Ariad Pharmaceuticals —“They are an oncology-based stock,” Landesman said. “They can do very well and likely to get approvals soon—we think they will eventually be taken over by Merck .”
Echo Therapeutics —“It also has a bright future,” he said.
Neoprobe —“Also expecting approvals there…We think it will be the source of a bidding war between their distributors Cardinal and Covidien.”
Landesman also likes Implant Sciences .
Scorecard—What He Said:
- Landesman's Previous Appearance on CNBC (Nov. 1, 2010)
More Market Views:
- Dennis Gartman Names His Top 3 Trades for 2011
- Positioning Your Portfolio Amid Global Fears: Pros
- Market 'Glass' Is 'Half-Full': BlackRock's Bob Doll
CNBC Data Pages:
No immediate information was available for Landesman or Tasho.